Glucose exposure after OGTT

1 paper1 finding

Human trial1

Interventions

1

ID110521156

downin humans1

1 study

ID110521156 decreases glucose exposure after OGTT in humans (-90.16, -102.44, and -124.69 mg·h/dL versus placebo -15.21 mg·h/dL).
“Glucose exposure after OGTT (ΔAUGC0-4) decreased dose dependently (-90.16, -102.44, and -124.69 mg·h/dL for 50, 100, and 200 mg) versus placebo (-15.21 mg·h/dL).”
Human trial28 days
ID110521156, a Novel Oral Small-Molecule GLP-1RA: Evidence of Favorable Safety Profile and Dose-Dependent Reduction in Body Weight and Glycemic Control after 28 Days of Treatment
ADA Scientific Sessions 2026 abstract5 Jun 2026

More on ID110521156

Latest

1 in 12 months

ADA Scientific Sessions 2026 Abstract5 Jun

ID110521156, a Novel Oral Small-Molecule GLP-1RA: Evidence of Favorable Safety Profile and Dose-Dependent Reduction in Body Weight and Glycemic Control after 28 Days of Treatment

Randomised trial in peopleInterventions